Remarkable Antidepressant Augmentation Effect of Raloxifene, a Selective Estrogen Receptor Modulator, in a Partial Responder to Fluvoxamine: A Case Report

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Although selective serotonin reuptake inhibitors (SSRIs) have a relatively low occurrence of adverse events, some patients cannot tolerate certain adverse reactions to SSRIs, such as nausea and dizziness. In these situations, patients often undergo a protracted course of depression because an effective dose cannot be administrated. We report a recent case of major depressive disorder in which the administration of raloxifene, a selective estrogen receptor modulator (SERM), in addition to a prior small dose of fluvoxamine, resulted in a remarkable improvement leading to a complete remission of depressive symptoms.’ ‹